EA200870246A1 - DERIVATIVES OF PIPERIDINE AS ANTAGONISTS OF CXCR3 RECEPTOR - Google Patents

DERIVATIVES OF PIPERIDINE AS ANTAGONISTS OF CXCR3 RECEPTOR

Info

Publication number
EA200870246A1
EA200870246A1 EA200870246A EA200870246A EA200870246A1 EA 200870246 A1 EA200870246 A1 EA 200870246A1 EA 200870246 A EA200870246 A EA 200870246A EA 200870246 A EA200870246 A EA 200870246A EA 200870246 A1 EA200870246 A1 EA 200870246A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heteroaryl
aryl
alkyl
formula
piperidine
Prior art date
Application number
EA200870246A
Other languages
Russian (ru)
Inventor
Эрвин Кусеманс
Жан-Пьер Андре Марк Бонгартз
Ги Розалия Эген Ван Ломмен
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200870246A1 publication Critical patent/EA200870246A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение относится к соединению формулы (I), его N-оксиду, его фармацевтически приемлемой соли, его стереохимически изомерной форме или его сольвату, где Х означает N или СН; Y означает прямую связь, СН-С(=O), где CHприсоединен к атому N пиперидинового цикла, С(=O) или S(=O); p означает целое число в значении 1 или 2; Rозначает СН(R)-арил или СН(R)-гетероарил; Rозначает арилили гетероарил; Rозначает водород, C-алкил, полигалоген-С-алкил, C-алкилокси, арил, арил-NH-, гетероарил, гетероарил-NH-, С-циклоалкил, амино или моно- или ди(C-алкил)амино. Настоящее изобретение также относится к применению соединения формулы (I) для получения лекарственного средства в целях предотвращения или лечения заболевания, опосредуемого активацией CXCR3-рецептора; к способам получения соединений формулы (I) и включающим их фармацевтическим композициям.The present invention relates to a compound of formula (I), its N-oxide, its pharmaceutically acceptable salt, its stereochemically isomeric form or its solvate, where X is N or CH; Y is a direct bond, CH — C (= O), where CH is attached to the N atom of the piperidine ring, C (= O) or S (= O); p is an integer in the value 1 or 2; R is CH (R) aryl or CH (R) heteroaryl; R is aryl or heteroaryl; R is hydrogen, C-alkyl, polyhalo-C-alkyl, C-alkyloxy, aryl, aryl-NH-, heteroaryl, heteroaryl-NH-, C-cycloalkyl, amino or mono- or di (C-alkyl) amino. The present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or treatment of a disease mediated by activation of the CXCR3 receptor; to methods for producing compounds of formula (I) and pharmaceutical compositions comprising them.

EA200870246A 2006-02-10 2007-02-06 DERIVATIVES OF PIPERIDINE AS ANTAGONISTS OF CXCR3 RECEPTOR EA200870246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101551 2006-02-10
PCT/EP2007/051123 WO2007090836A2 (en) 2006-02-10 2007-02-06 Piperidine derivatives as cxcr3 receptor antagonists

Publications (1)

Publication Number Publication Date
EA200870246A1 true EA200870246A1 (en) 2009-02-27

Family

ID=35911097

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870246A EA200870246A1 (en) 2006-02-10 2007-02-06 DERIVATIVES OF PIPERIDINE AS ANTAGONISTS OF CXCR3 RECEPTOR

Country Status (13)

Country Link
EP (1) EP1983986A2 (en)
JP (1) JP2009526016A (en)
KR (1) KR20080093040A (en)
CN (1) CN101378756A (en)
AR (1) AR059427A1 (en)
AU (1) AU2007213744A1 (en)
BR (1) BRPI0707629A2 (en)
CA (1) CA2635138A1 (en)
EA (1) EA200870246A1 (en)
IL (1) IL193295A0 (en)
NO (1) NO20083856L (en)
TW (1) TW200811131A (en)
WO (1) WO2007090836A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125578A (en) * 1962-05-17 1964-03-17 xxviii
IL159256A0 (en) * 2001-07-02 2004-06-01 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
CA2635138A1 (en) 2007-08-16
CN101378756A (en) 2009-03-04
WO2007090836A3 (en) 2007-11-29
TW200811131A (en) 2008-03-01
IL193295A0 (en) 2009-08-03
EP1983986A2 (en) 2008-10-29
JP2009526016A (en) 2009-07-16
BRPI0707629A2 (en) 2011-05-10
KR20080093040A (en) 2008-10-17
NO20083856L (en) 2008-11-04
AR059427A1 (en) 2008-04-09
WO2007090836A2 (en) 2007-08-16
AU2007213744A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CY1117576T1 (en) NUCLEOTIC PRODUCTS
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
CY1117330T1 (en) Benzodioxinyl Substituted Indazolium Derivatives
ATE517882T1 (en) QUINOLINE DERIVATIVES
MA32812B1 (en) Pharmaceutical composition of a powerful antagonist for oral VHC
CY1113269T1 (en) INDIAZOLYL AMID PRODUCT FOR THE THERAPEUTIC TREATMENT OF GLUCCORTIC MEDICINES
NO20072371L (en) Kinuclidine derivatives and their use as muscarinic M3 receptor antagonists
DK1723138T3 (en) Substituted benzimidazoles and their use to induce apoptosis
EA200801909A1 (en) PYRIDINE COMPOUNDS FOR THE TREATMENT OF DISEASES MEDIATED BY PROSTAGLANDINE
EA201101398A1 (en) SUBSTITUTED PIPERIDINE AS AN ANTAGONIST CCR3
AR086546A1 (en) DERIVATIVES OF 7H-PURIN-8 (9H) -ONA AS JAK INHIBITORS
TW200612936A (en) Indole derivatives
ATE440834T1 (en) SUBSTITUTED ARYLAMIN DERIVATIVES AND METHODS OF USE
AR074855A1 (en) AMINOESTER DERIVATIVES OF ALCALOIDS AND MEDICINAL COMPOSITION OF THE SAME USES IN THE TREATMENT OF DISEASES MEDIATED BY THE ANTAGONISM OF MUSCARINIC RECEPTORS.
MX2009012613A (en) Heteroaryl substituted thiazoles and their use as antiviral agents.
JO2937B1 (en) Peptidic Vasopressin Receptor Agonists
NO20070837L (en) Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer.
RU2009144538A (en) NEW CYCLIC PEPTIDE COMPOUNDS
IN2012DN02502A (en)
DE602007001463D1 (en) PYRIMIDINE, CHINAZOLIN, PTERIDINE AND TRIAZINE DERIVATIVES
AR061185A1 (en) HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS.
MX2013012555A (en) Novel rock inhibitors.
AR081966A1 (en) AMINOESTER DERIVATIVES OF ALCALOIDS AND MEDICINAL COMPOSITION OF THE SAME
BRPI0517734A (en) 1 - [(6,7-substituted alkoxyquinoxalinyl) aminocarbonyl] -4- (hetero) arylpiperazine derivatives
TW200505869A (en) Thiophenylaminoimidazolines